Boston Scientific price target raised to $124 from $120 at BTIG

BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $124 from $120 and keeps a Buy rating on the shares after the company reported quarterly results. The firm expects Boston Scientific to remain a high-quality MedTech stock, and as a result raised its price target based on 36x its 12-24 month adjusted earnings per share forecast. In the quarterly report, management pointed to the strength of its sales upside from cardiology, some forex benefit, and targeted reduction in discretionary spending as driving their ability to absorb the roughly $200M in tariff impacts largely in 2H25, the analyst tells investors in a research note.